Will France's tighter medtech reimbursement rules leave industry room to manoeuvre?
This article was originally published in Clinica
Executive Summary
France is using its reimbursement system to introduce more onerous requirements than for CE marking. In the second article in Clinica's series on EU reimbursement and HTA, Dr Mark Charny, managing director of UK-based consultancy Translucency, analyses the impact of the latest challenges to having products reimbursed under increasingly stringent French rules
You may also be interested in...
WINDOW INTO HTA: Assessing The Reimbursement Climate For Your Product
In the final part of Clinica’s series on heath technology assessment in the EU, Mark Charny looks beyond HTA and discusses what factors to consider when gauging the reimbursement potential of your product from a payer’s perspective
WINDOW INTO HTA: Planning A Resource-Effective Strategy
In the second part of Clinica’s new series on health technology assessment in the EU, Mark Charny discusses how medtech companies can plan their HTA strategy on a country-specific level and on a broader EU level
Window Into Medical Devices: Where Is the EU At With Its HTA Network?
Mark Charny provides an update on the key initiatives that have been rolled out in the EU to support cross-border collaboration on health technology assessment for medical devices.